Developer docs
API playgroundTry for free, no card

Search company profiles

SeLux Diagnostics

Full company profile

uuid0000osz

Namestring
SeLux Diagnostics
Legal namestring
Selux Diagnostics
Websiteurl
seluxdx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

SeLux Diagnostics is a Boston-based medical device company founded in 2014 that has developed the Next-Generation Phenotyping (NGP) platform, a rapid antimicrobial susceptibility testing (AST) system. The platform delivers same-shift AST results, enabling clinicians to make personalized antibiotic treatment decisions within 24 hours rather than the multiple days required by traditional AST methods. The company targets U.S. hospitals and healthcare systems seeking faster infectious disease diagnostics to support antibiotic stewardship programs and address antimicrobial resistance.

The NGP platform is the company's sole commercial product, sold to U.S. hospitals through an enterprise field sales motion with revenue generated from instrument sales and related consumables/tests. Pricing is not publicly disclosed. The platform received FDA Breakthrough Device Designation in 2021, providing expedited regulatory review, and SeLux completed clinical trials prior to initiating its U.S. commercial launch. The company has positioned NGP as a potential new standard for infectious disease diagnostics, with go-to-market centered on hospitals requiring same-shift results to impact patient care and antimicrobial stewardship decisions.

SeLux has raised approximately $220 million in cumulative funding through April 2024 across multiple rounds, including a Series C ($50 million, February 2022) and a Series 3 ($48 million, April 2024), with equity investors including Northpond Ventures, RA Capital Management, Sands Capital Ventures, and Schooner Capital. Non-dilutive capital includes a BARDA contract potentially worth $60.8 million, a $30 million senior secured debt facility from Oxford Finance (June 2022), a $14.6 million BARDA award (June 2021), and a $2.8 million NIH grant (October 2021). Leadership comprises CEO Steve Lufkin, co-founders Aleksandar Vacic (President) and Eric Stern (CTO), and Chief Commercial Officer John Wilson, who leads the U.S. commercial team buildout.

Short descriptiontext

SeLux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing, delivering same-shift results to U.S. hospitals to enable personalized antibiotic treatments within 24 hours.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial susceptibility testing, infectious disease diagnostics, phenotyping diagnostic platform, clinical microbiology devices, rapid AST diagnostics
Industry1 code
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Microbiology / In Vitro Diagnostics (Antimicrobial Susceptibility Testing)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Diagnostics
TypeHardware Sales
Description

Sale of rapid antimicrobial susceptibility testing platform and related consumables/tests for infectious disease diagnostics in healthcare settings

abfjournal.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Next-Generation Phenotyping (NGP) Platform
Description

Rapid antimicrobial susceptibility testing platform that provides same-shift results for infectious disease diagnosis and antibiotic stewardship.

vcaonline.com
Core offering1 text field

SeLux Diagnostics develops and commercializes the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing (AST) system that delivers same-shift phenotypic results so clinicians can select personalized antibiotic therapy within 24 hours. The platform combines a diagnostic instrument with proprietary consumables/tests and is intended to support infectious disease diagnosis and antibiotic stewardship in hospital and clinical microbiology settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Results available same-shift, enabling personalized treatment within 24 hours
Product overview1 text field

SeLux Diagnostics offers a single unified product: the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing system designed to provide same-shift AST results within 24 hours. The platform is intended to establish a new standard for infectious disease diagnostics by enabling personalized antibiotic treatments and supporting antibiotic stewardship programs. The company is commercializing this platform in the U.S. market following clinical trials and FDA breakthrough device designation.

Product and service1 record
1Next-Generation Phenotyping (NGP) Platform
CategoryClinical Microbiology / In Vitro Diagnostics
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Direct competitor in rapid phenotypic antimicrobial susceptibility testing; its Pheno system provides accelerated ID/AST results for bloodstream infections—the same clinical use case SeLux targets with NGP.

TypeDirect peer
Description

Swedish developer of the ASTar rapid AST system, directly comparable as a same-shift phenotypic AST platform targeting hospital microbiology labs with high-throughput requirements.

TypeEmerging player
Description

Emerging competitor in rapid phenotypic AST using a proprietary metabolism-based technology, pursuing similar same-shift AST value proposition for hospital labs.

TypeBroad incumbent
Description

Global IVD incumbent with the VITEK automated AST system and extensive microbiology menu; competes broadly with SeLux through installed-base economics and is also developing faster AST solutions.

TypeBroad incumbent
Description

Large diagnostics incumbent with BD Phoenix and BD MAX microbiology/AST systems and a broad installed base in hospital labs; comparable as both a competitor and potential strategic acquirer.

TypeDirect peer
Description

Rapid molecular diagnostics company addressing bloodstream infections and sepsis with same-shift results; competes for the same hospital antimicrobial stewardship and time-to-treatment budget.

TypeOthers
Description

Specimen collection and automated sample-prep provider serving hospital microbiology labs; relevant as an ecosystem participant whose automation integrates with downstream AST platforms like NGP.

TypeRegional player
Description

U.S.-based microbiology supplies and culture media manufacturer with a regional footprint in clinical microbiology; comparable as an adjacent supplier into the same hospital lab customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SeLux Diagnostics

Clinical Microbiology / In Vitro Diagnostics (Antimicrobial Susceptibility Testing)seluxdx.com

SeLux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing, delivering same-shift results to U.S. hospitals to enable personalized antibiotic treatments within 24 hours.

What SeLux Diagnostics does

SeLux Diagnostics is a Boston-based medical device company founded in 2014 that has developed the Next-Generation Phenotyping (NGP) platform, a rapid antimicrobial susceptibility testing (AST) system. The platform delivers same-shift AST results, enabling clinicians to make personalized antibiotic treatment decisions within 24 hours rather than the multiple days required by traditional AST methods. The company targets U.S. hospitals and healthcare systems seeking faster infectious disease diagnostics to support antibiotic stewardship programs and address antimicrobial resistance.

The NGP platform is the company's sole commercial product, sold to U.S. hospitals through an enterprise field sales motion with revenue generated from instrument sales and related consumables/tests. Pricing is not publicly disclosed. The platform received FDA Breakthrough Device Designation in 2021, providing expedited regulatory review, and SeLux completed clinical trials prior to initiating its U.S. commercial launch. The company has positioned NGP as a potential new standard for infectious disease diagnostics, with go-to-market centered on hospitals requiring same-shift results to impact patient care and antimicrobial stewardship decisions.

SeLux has raised approximately $220 million in cumulative funding through April 2024 across multiple rounds, including a Series C ($50 million, February 2022) and a Series 3 ($48 million, April 2024), with equity investors including Northpond Ventures, RA Capital Management, Sands Capital Ventures, and Schooner Capital. Non-dilutive capital includes a BARDA contract potentially worth $60.8 million, a $30 million senior secured debt facility from Oxford Finance (June 2022), a $14.6 million BARDA award (June 2021), and a $2.8 million NIH grant (October 2021). Leadership comprises CEO Steve Lufkin, co-founders Aleksandar Vacic (President) and Eric Stern (CTO), and Chief Commercial Officer John Wilson, who leads the U.S. commercial team buildout.

SeLux Diagnostics firmographics

Firmographics
Name
SeLux Diagnostics
Legal name
Selux Diagnostics
Website
https://seluxdx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
SeLux Diagnostics is a Boston-based medical device company developing the Next-Generation Phenotyping (NGP) platform for rapid antimicrobial susceptibility testing, delivering same-shift results to U.S. hospitals to enable personalized antibiotic treatments within 24 hours.
Ownership category
akta.pro rank

SeLux Diagnostics industry classification

Industry
Product category
Clinical Microbiology / In Vitro Diagnostics (Antimicrobial Susceptibility Testing)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Antimicrobial susceptibility testing
  • Infectious disease diagnostics
  • Phenotyping diagnostic platform
  • Clinical microbiology devices
  • Rapid AST diagnostics

Where SeLux Diagnostics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SeLux Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Medical Device Diagnostics: Sale of rapid antimicrobial susceptibility testing platform and related consumables/tests for infectious disease diagnostics in healthcare settings

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

SeLux Diagnostics product offering

Product offering

Core offering

SeLux Diagnostics develops and commercializes the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing (AST) system that delivers same-shift phenotypic results so clinicians can select personalized antibiotic therapy within 24 hours. The platform combines a diagnostic instrument with proprietary consumables/tests and is intended to support infectious disease diagnosis and antibiotic stewardship in hospital and clinical microbiology settings.

Product overview

SeLux Diagnostics offers a single unified product: the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing system designed to provide same-shift AST results within 24 hours. The platform is intended to establish a new standard for infectious disease diagnostics by enabling personalized antibiotic treatments and supporting antibiotic stewardship programs. The company is commercializing this platform in the U.S. market following clinical trials and FDA breakthrough device designation.

Differentiator

Problem solved

Functional benefit

Brands

  • Next-Generation Phenotyping (NGP) Platform: Rapid antimicrobial susceptibility testing platform that provides same-shift results for infectious disease diagnosis and antibiotic stewardship.

Products and services

  • Next-Generation Phenotyping (NGP) Platform

Quantifiable outcome

  • Results available same-shift, enabling personalized treatment within 24 hours

Companies that use SeLux Diagnostics

Customer profile

Segments1 record

Ideal customer profiles1 record

SeLux Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SeLux Diagnostics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

SeLux Diagnostics competitors and assessment

Company assessment

Direct peers

  • Accelerate Diagnostics: Direct competitor in rapid phenotypic antimicrobial susceptibility testing; its Pheno system provides accelerated ID/AST results for bloodstream infections—the same clinical use case SeLux targets with NGP.
  • Q-linea: Swedish developer of the ASTar rapid AST system, directly comparable as a same-shift phenotypic AST platform targeting hospital microbiology labs with high-throughput requirements.
  • T2 Biosystems: Rapid molecular diagnostics company addressing bloodstream infections and sepsis with same-shift results; competes for the same hospital antimicrobial stewardship and time-to-treatment budget.

Emerging players

  • Specific Diagnostics: Emerging competitor in rapid phenotypic AST using a proprietary metabolism-based technology, pursuing similar same-shift AST value proposition for hospital labs.

Broad incumbents

  • BioMérieux: Global IVD incumbent with the VITEK automated AST system and extensive microbiology menu; competes broadly with SeLux through installed-base economics and is also developing faster AST solutions.
  • Becton Dickinson (BD): Large diagnostics incumbent with BD Phoenix and BD MAX microbiology/AST systems and a broad installed base in hospital labs; comparable as both a competitor and potential strategic acquirer.

Others

  • Copan Diagnostics: Specimen collection and automated sample-prep provider serving hospital microbiology labs; relevant as an ecosystem participant whose automation integrates with downstream AST platforms like NGP.

Regional players

  • Hardy Diagnostics: U.S.-based microbiology supplies and culture media manufacturer with a regional footprint in clinical microbiology; comparable as an adjacent supplier into the same hospital lab customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

SeLux Diagnostics social profiles

Digital presence

SeLux Diagnostics compliance and trust

Trust signal

Compliance1 record

SeLux Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SeLux Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

SeLux Diagnostics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SeLux Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SeLux Diagnostics

What does SeLux Diagnostics do?

SeLux Diagnostics develops and commercializes the Next-Generation Phenotyping (NGP) Platform, a rapid antimicrobial susceptibility testing (AST) system that delivers same-shift phenotypic results so clinicians can select personalized antibiotic therapy within 24 hours. The platform combines a diagnostic instrument with proprietary consumables/tests and is intended to support infectious disease diagnosis and antibiotic stewardship in hospital and clinical microbiology settings.

Is SeLux Diagnostics a public or private company?

SeLux Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was SeLux Diagnostics founded?

SeLux Diagnostics was founded in 2014. It employs 11 to 50 people.

Where is SeLux Diagnostics based?

SeLux Diagnostics is headquartered in Boston, United States, in the North America region.

How does SeLux Diagnostics make money?

One revenue line is on record: medical Device Diagnostics.

Who are SeLux Diagnostics's main competitors?

Direct peers on record are Accelerate Diagnostics, Q-linea and T2 Biosystems. Specific Diagnostics is listed as an emerging player. Broad incumbents are BioMérieux and Becton Dickinson (BD). Copan Diagnostics is listed as an others. Hardy Diagnostics is listed as a regional player.

Does SeLux Diagnostics have an API?

No public API is recorded for SeLux Diagnostics.

What industry is SeLux Diagnostics in?

SeLux Diagnostics's product category is Clinical Microbiology / In Vitro Diagnostics (Antimicrobial Susceptibility Testing). Its primary akta.pro industry code is HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™The sepsis diagnostics market is projected to grow from $0.83 billion in 2026 to $1.22 billion by 2031, a 7.9% CAGR. North America held the largest regional share at 43.2% in 2025, and assays & reagent kits led the product segment. Growth is driven by rising sepsis incidence and demand for rapid diagnostics.Tracxn2026 Funding Rounds & List of InvestorsThe article presents a tabular list of historical funding rounds for SeLux Diagnostics, detailing dates, amounts, and investors from 2016 to 2024. It includes specific data points such as Series B and C rounds, grants, and associated valuations. The content is purely informational and lacks narrative context regarding strategic developments.GlobeNewswireLateral Flow Assay Market Projected to Reach US$ 17.66 Billion by 2035, Reflecting Ongoing Innovation and IP Activity | Astute AnalyticaThe global lateral flow assay market was valued at USD 10.84 billion in 2025 and is projected to reach USD 17.66 billion by 2035, growing at a compound annual growth rate of 5.0% over the forecast period 2026–2035, driven by post-pandemic healthcare shifts, rising infectious disease burdens, and expanded government testing contracts. The market is segmented by product (LFA kits commanding 71.9% share), indication (infectious diseases at 72.2%), technique (sandwich assay at 48%), and end users (hospitals and clinics at 38.8%), with key players including QuidelOrtho, Abbott, and others investing in multiplex testing, nanoparticle sensitivity enhancements, and digital reader technologies. Regulatory approvals are accelerating, with the FDA issuing 1,507 510(k) clearances in the first half of 2024, while BARDA and NIH funding are de-risking R&D through contracts such as the USD 40.9 million award to Pattern Bioscience and the USD 45 million contract to Selux Diagnostics.Pulse 2.0Selux Diagnostics: $48 Million Closed To Combat Superbug Infections And Fight Antimicrobial ResistanceSelux Diagnostics has closed a $48 million funding round led by RA Capital Management to support the commercialization of its NGP System in the US. The platform is an FDA-cleared rapid antibiotic susceptibility testing technology that provides results in hours, significantly faster than current standards.citybizSands Capital Joins $48 Million Funding Round for Selux DiagnosticsSands Capital has joined a $48 million funding round for biotech startup Selux Diagnostics, which was led by RA Capital Management with participation from Northpond Ventures and Schooner Capital. This investment brings Selux's total raised capital to $220.5 million as it prepares to commercialize its FDA-cleared next-generation phenotyping system to combat antimicrobial resistance. The platform aims to enable personalized antibiotic therapies and improve patient care outcomes.PharmiWeb.comSelux Diagnostics Announces Additional $48 Million in FundingSelux Diagnostics announced an additional $48 million in funding to commercialize its NGP rapid AST system in the U.S. The company also received its third FDA 510(k) clearance, making it the only single-platform technology delivering same-day AST results for both positive blood culture and isolated colonies.PharmiWeb.comSelux Diagnostics Announces Additional $48 Million in FundingSelux Diagnostics announced an additional $48 million in funding to commercialize its NGP rapid AST system in the U.S. The company also received its third FDA 510(k) clearance, making it the only single-platform rapid AST technology for both positive blood culture and isolated colonies.MorningstarSelux Diagnostics Announces Additional $48 Million in FundingSelux Diagnostics announced an additional $48 million in funding to commercialize its NGP rapid AST system in the U.S. The company also received its third FDA 510(k) clearance, making it the only single-platform technology delivering same-day AST results for both positive blood culture and isolated colonies.Business InsiderSelux Diagnostics Announces Additional $48 Million in FundingSelux Diagnostics announced an additional $48 million in funding to commercialize its NGP rapid AST system in the U.S. The company also received its third FDA 510(k) clearance, making it the only single-platform technology delivering same-day AST results for both positive blood culture and isolated colonies.PR NewswireFDA Roundup: February 16, 2024The FDA provided its weekly roundup of agency actions, including the conversion of tepotinib (Tepmetko) from accelerated to traditional approval for metastatic non-small cell lung cancer and the approval of irinotecan liposome (Onivyde) for first-line treatment of metastatic pancreatic adenocarcinoma. The agency also cleared two antimicrobial susceptibility testing systems—the PBC Separator with Selux AST System from Selux Diagnostics and the eQUANT System from Avails Medical—for marketing in the U.S. Additionally, the FDA continued updating the public on the Listeria monocytogenes outbreak linked to Cotija and Queso Fresco cheeses from Rizo-Lopez Foods, Inc., with additional recalls being issued.